If you’re looking at Bayer stock right now and wondering whether to buy, hold, or move on, you’re not alone. The company’s recent price action has given investors plenty to think about. After a tough slide earlier in the year, Bayer shares have shown resilience, bouncing back with a 41.4% gain year-to-date. However, the last week saw a drop of 7.5%. The one-year return sits just above break-even at 1.1%, while the longer-term three- and five-year returns are still underwater, down 41.4% and 30.3% respectively. In short, Bayer’s price story reflects recovery against a challenging longer-term backdrop.

Market sentiment has shifted around Bayer lately, with cautious optimism weighing against unresolved risks in the background. Investors seem to be re-evaluating the company; some are betting on a comeback, while others are wary of getting caught out by volatility. It is worth noting that, based on a solid set of valuation checks, Bayer scores a 5 out of 6 when it comes to being undervalued. That might catch your eye if you are searching for stocks trading at less than their intrinsic value.

But of course, a number alone rarely tells the full story. Next, we will dive into how analysts arrive at these valuation numbers and what methods are best for figuring out if Bayer truly deserves a place in your portfolio. For an even smarter way to slice through the noise, stay tuned to the very end.

Bayer delivered 1.1% returns over the last year. See how this stacks up to the rest of the Pharmaceuticals industry.

The Discounted Cash Flow (DCF) model determines what a business is worth by forecasting its future cash flows and then discounting them back to their value today. Essentially, this model gives an estimate of Bayer’s intrinsic value based on how much cash the company is expected to generate going forward.

For Bayer, the DCF model starts with a Last Twelve Months (LTM) Free Cash Flow (FCF) of approximately €4.41 billion. Analyst projections take these numbers further, anticipating steady growth. By 2029, forecasts show free cash flow reaching around €6.15 billion. For years where analyst estimates run out, projections are extrapolated based on recent trends and growth rates. This approach builds a comprehensive picture of Bayer’s future earning potential over the next decade.

According to the DCF calculation, Bayer’s estimated intrinsic value comes in at €167.92 per share. When measured against its recent share price, this implies an 83.7% undervaluation. In other words, the stock is trading at just a fraction of what its future cash flow potential suggests it could be worth.

Result: UNDERVALUED

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Bayer.

Our Discounted Cash Flow (DCF) analysis suggests Bayer is undervalued by 83.7%. Track this in your watchlist or portfolio, or discover more undervalued stocks.

The Price-to-Sales (P/S) ratio is a particularly useful metric for valuing companies like Bayer, especially in industries where profits may be limited by heavy R&D investment, litigation risks, or other temporary factors. The P/S ratio helps investors put current sales in context, smoothing out short-term swings in profitability and illuminating the market’s expectations for revenue growth.

Whether a “normal” P/S ratio is high or low depends on factors like growth potential, industry risk, and how much future earnings are already baked into the price. Companies with higher expected growth or lower risk generally command higher P/S multiples, while those with flat outlooks or significant uncertainties tend to trade lower.

Bayer’s current P/S ratio stands at just 0.58x, markedly below both its peer average (1.97x) and the pharmaceutical industry average (2.81x). At a glance, this might make Bayer look like a bargain compared to its sector. However, Simply Wall St’s proprietary “Fair Ratio” model assigns Bayer a fair value multiple of 1.45x. This figure is derived from careful consideration of the company's growth trajectory, industry profile, margins, market size, and specific risks. This approach provides deeper perspective than a straightforward industry or peer comparison, since it tailors expectations to Bayer’s unique situation.

Comparing Bayer’s actual P/S of 0.58x to its fair ratio of 1.45x, the stock appears to be undervalued on a sales basis, suggesting that the market might not be fully appreciating its revenue-generating potential.

Result: UNDERVALUED

PS ratios tell one story, but what if the real opportunity lies elsewhere? Discover companies where insiders are betting big on explosive growth.

Earlier we mentioned there's an even better way to understand valuation, so let's introduce you to Narratives. A Narrative is more than just numbers; it is your perspective or story about a company, backed by your own assumptions about its future revenue, margins, and fair value.

This approach connects the dots between what you know (the company’s business and catalysts), your beliefs about the future (your forecast), and what you think the stock is worth (your fair value), all in one place. Narratives are available on Simply Wall St’s Community page, giving millions of investors an easy and accessible tool for smarter decision making.

With Narratives, you can decide whether to buy or sell by comparing your calculated Fair Value to today’s share price. Plus, your Narrative updates dynamically as new news or earnings reports arrive, so your valuations stay relevant and actionable.

For example, some Bayer investors are optimistic and see immense long-term upside, setting price targets as high as €39.0, while others are more cautious with targets as low as €23.0. This demonstrates how different stories can lead to different actions.

Do you think there's more to the story for Bayer? Create your own Narrative to let the Community know!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include BAYN.xtra.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com